Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors

Cellular Oncology

Volumn 35, Issue 6, 2012, Pages 397-409

  Liu, Wei Hui ^a,b   You, Nan ^b   Zhang, Ning ^b   Yan, Hong Tao ^a   Wang, Tao ^a   Huang, Zhu ^a   Liu, Hong Bao ^b   Tang, Li Jun ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cells (CSCs); Hepatic cancer stem cells (HCSCs); Identification; Isolation; Origin; Therapy

Indexed keywords

CELL SURFACE MARKER; FLUORESCENT DYE;

CANCER STEM CELL; CANCER THERAPY; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL FUSION; CELL ISOLATION; CELL KILLING; CELL SEPARATION; EFFUSION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SAFETY; SOLID TUMOR; ANIMAL; EPITHELIAL MESENCHYMAL TRANSITION; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; RADIATION EXPOSURE;

ANIMALS; CELL SEPARATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84879201469     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-012-0110-8     Document Type: Review

References (97)

1. H. Clevers, The cancer stem cell: Premises, promises and challenges. Nat. Med. 17(3), 313-319 (2011)
2. T. Ikegami, Transforming growth factor-beta signaling and liver cancer stem cell. Hepatol Res. 39(9), 847-849 (2009)
3. M.F. Clarke, J.E. Dick, P.B. Dirks, C.J. Eaves, C.H. Jamieson, D.L. Jones et al., Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66(19), 9339-9344 (2006)
4. M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. McNamara et al., Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12(19), 5615-5621 (2006)
5. G. Gu, J. Yuan, M. Wills, S. Kasper, Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 67(10), 4807-4815 (2007)
6. S. Takaishi, T. Okumura, S. Tu, S.S. Wang, W. Shibata, R. Vigneshwaran et al., Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27(5), 1006-1020 (2009)
7. M. Todaro, M.G. Francipane, J.P. Medema, G. Stassi, Colon cancer stem cells: Promise of targeted therapy. Gastroenterology 138 (6), 2151-2162 (2010)
8. T. Chiba, A. Kamiya, O. Yokosuka, A. Iwama, Cancer stem cells in hepatocellular carcinoma: Recent progress and perspective. Cancer Lett. 286(2), 145-153 (2009)
9. T. Shupe, B.E. Petersen, Evidence regarding a stem cell origin of hepatocellular carcinoma. Stem Cell Rev. 1(3), 261-264 (2005)
10. M. Baddoo, K. Hill, R. Wilkinson, D. Gaupp, C. Hughes, G.C. Kopen et al., Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J. Cell. Biochem. 89(6), 1235-1249 (2003)
11. F.I. Ghani, H. Yamazaki, S. Iwata, T. Okamoto, K. Aoe, K. Okabe et al., Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem. Biophys. Res. Commun. 404 (2), 735-742 (2011)
12. S. Shigdar, J. Lin, Y. Yu, M. Pastuovic, M. Wei, W. Duan, RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 102(5), 991-998 (2011)
13. K. Kohga, T. Tatsumi, T. Takehara, H. Tsunematsu, S. Shimizu, M. Yamamoto et al., Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J. Hepatol. 52(6), 872-879 (2010)
14. L. Vermeulen, M. Todaro, F. de Sousa Mello, M.R. Sprick, K. Kemper, M. Perez Alea et al., Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl. Acad. Sci. U. S. A. 105(36), 13427-13432 (2008)
15. L.S. Hart, N.G. Dolloff, D.T. Dicker, C. Koumenis, J.G. Christensen, A. Grimberg et al., Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 10(14), 2331-2338 (2011)
16. F.J. Abdul Khalek, G.I. Gallicano, L. Mishra, Colon cancer stem cells. Gastrointest Cancer Res 1, S16-S23 (2010)
17. W. Song, H. Li, K. Tao, R. Li, Z. Song, Q. Zhao et al., Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 62(8), 1212-1218 (2008)
18. T. Nagata, C. Sakakura, S. Komiyama, A. Miyashita, M. Nishio, Y. Murayama et al., Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res. 31(2), 495-500 (2011)
19. T. Yamashita, J. Ji, A. Budhu, M. Forgues, W. Yang, H.Y. Wang et al., EpCAM-positive hepatocellular carcinoma cells are tumorinitiating cells with stem/progenitor cell features. Gastroenterology 136(3), 1012-1024 (2009)
20. Z.F. Yang, P. Ngai, D.W. Ho, W.C. Yu, M.N. Ng, C.K. Lau et al., Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47(3), 919-928 (2008)
21. H. Yanai, K. Nakamura, S. Hijioka, A. Kamei, T. Ikari, Y. Ishikawa et al., Dlk-1, a cell surface antigen on foetal hepatic stem/progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcinomas at a high frequency. J. Biochem. 148(1), 85-92 (2010)
22. B. Christ, P. Stock, M.M. Dollinger, CD13: Waving the flag for a novel cancer stem cell target. Hepatology 53(4), 1388-1390 (2011)
23. W. Yang, H.X. Yan, L. Chen, Q. Liu, Y.Q. He, L.X. Yu et al., Wnt/ beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 68(11), 4287-4295 (2008)
24. S. Lingala, Y.Y. Cui, X. Chen, B.H. Ruebner, X.F. Qian, M.A. Zern et al., Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp. Mol. Pathol. 89(1), 27-35 (2010)
25. Z. Zhu, X. Hao, M. Yan, M. Yao, C. Ge, J. Gu et al., Cancer stem/ progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer 126(9), 2067-2078 (2010)
26. X.R. Yang, Y. Xu, B. Yu, J. Zhou, S.J. Qiu, G.M. Shi et al., High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59(7), 953-962 (2010)
27. T. Fujii, Y. Zen, K. Harada, H. Niwa, S. Masuda, Y. Kaizaki et al., Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma-human and cell culture study. Hum. Pathol. 39(8), 1185-1196 (2008)
28. M.A. Goodell, K. Brose, G. Paradis, A.S. Conner, R.C. Mulligan, Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183(4), 1797-1806 (1996)
29. G.J. Spangrude, G.R. Johnson, Resting and activated subsets of mouse multipotent hematopoietic stem cells. Proc Natl Acad Sci USA 87(19), 7433-7437 (1990)
30. A. Asakura, P. Seale, A. Girgis-Gabardo, M.A. Rudnicki, Myogenic specification of side population cells in skeletal muscle. J. Cell Biol. 159(1), 123-134 (2002)
31. A.J. Alvi, H. Clayton, C. Joshi, T. Enver, A. Ashworth, M.M. Vivanco et al., Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 5(1), R1-R8 (2003)
32. K. Shimano, M. Satake, A. Okaya, J. Kitanaka, N. Kitanaka, M. Takemura et al., Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am. J. Pathol. 163(1), 3-9 (2003)
33. C.M. Dekaney, J.M. Rodriguez, M.C. Graul, S.J. Henning, Isolation and characterization of a putative intestinal stem cell fraction from mouse jejunum. Gastroenterology 129(5), 1567-1580 (2005)
34. M. Ono, T. Maruyama, H. Masuda, T. Kajitani, T. Nagashima, T. Arase et al., Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc. Natl. Acad. Sci. U.S.A. 104(47), 18700-18705 (2007)
35. T. Chiba, K. Kita, Y.W. Zheng, O. Yokosuka, H. Saisho, A. Iwama et al., Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44(1), 240-251 (2006)
36. G.M. Shi, Y. Xu, J. Fan, J. Zhou, X.R. Yang, S.J. Qiu et al., Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J. Cancer Res. Clin. Oncol. 134(11), 1155-1163 (2008)
37. Y. Zhang, W.J. Song, F.Q. Zhang, W.H. Liu, K.F. Dou, Differentiation- inducing activity of hydroxycamptothecin on cancer stem-like cells derived from hepatocellular carcinoma. Dig. Dis. Sci. 56(8), 2473-2481 (2011)
38. W.H. Liu, N.S. Qian, R. Li, K.F. Dou, Replacing Hoechst33342 with rhodamine123 in isolation of cancer stem-like cells from the MHCC97 cell line. Toxicol. In Vitro 24(2), 538-545 (2010)
39. W.H. Liu, K.S. Tao, N. You, Z.C. Liu, H.T. Zhang, K.F. Dou, Differences in the Properties and Mirna Expression Profiles between Side Populations from Hepatic Cancer Cells and Normal Liver Cells. PLoS One 6(8), e23311 (2011)
40. Z. Song, R. Li, N. You, K. Tao, K. Dou, Loss of heterozygosity of the tumor suppressor gene Tg737 in the side population cells of hepatocellular carcinomas is associated with poor prognosis. Mol. Biol. Rep. 37(8), 4091-4101 (2010)
41. A. Golebiewska, N.H. Brons, R. Bjerkvig, S.P. Niclou, Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 8(2), 136-147 (2011)
42. F. Montanaro, K. Liadaki, J. Schienda, A. Flint, E. Gussoni, L.M. Kunkel, Demystifying SP cell purification: Viability, yield, and phenotype are defined by isolation parameters. Exp. Cell Res. 298 (1), 144-154 (2004)
43. C. Ferlini, G. Scambia, Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange. Nat. Protoc. 2(12), 3111-3114 (2007)
44. A.C. Ribou, J. Vigo, E. Kohen, J.M. Salmon, Microfluorometric study of oxygen dependence of (1″-pyrene butyl)-2-rhodamine ester probe in mitochondria of living cells. J. Photochem. Photobiol. B 70(2), 107-115 (2003)
45. C. Wu, B.A. Alman, Side population cells in human cancers. Cancer Lett. 268(1), 1-9 (2008)
46. A.M. Rosca, A. Burlacu, Isolation of a mouse bone marrow population enriched in stem and progenitor cells by centrifugation on a Percoll gradient. Biotechnol. Appl. Biochem. 55(4), 199-208 (2010)
47. Y. Chang, P.H. Hsieh, C.C. Chao, The efficiency of Percoll and Ficoll density gradient media in the isolation of marrow derived human mesenchymal stem cells with osteogenic potential. Chang Gung Med. J. 32(3), 264-275 (2009)
48. W.H. Liu, R. Li, K.F. Dou, Convenient and efficient enrichment of the CD133+ liver cells from rat fetal liver cells as a source of liver stem/progenitor cells. Stem Cell Rev. 7(1), 94-102 (2011)
49. W.H. Liu, X. Wang, N. You, K.S. Tao, T. Wang, L.J. Tang et al., Efficient Enrichment of Hepatic Cancer Stem-Like Cells from a Primary Rat HCC Model via a Density Gradient Centrifugation-Centered Method. PLoS One 7(4), e35720 (2012)
50. N.A. Lobo, Y. Shimono, D. Qian, M.F. Clarke, The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 23, 675-699 (2007)
51. M.F. Clarke, M. Fuller, Stem cells and cancer: Two faces of eve. Cell 124(6), 1111-1115 (2006)
52. X. Lu, Y. Kang, Cell fusion hypothesis of the cancer stem cell. Adv. Exp. Med. Biol. 714, 129-140 (2011)
53. T. Yamashita, M. Honda, K. Nio, Y. Nakamoto, H. Takamura, T. Tani et al., Oncostatin m renders epithelial cell adhesion moleculepositive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res. 70(11), 4687-4697 (2010)
54. R. Taghizadeh, M. Noh, Y.H. Huh, E. Ciusani, L. Sigalotti, M. Maio et al., CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS One 5(12), e15183 (2010)
55. A.G. Schepers, H.J. Snippert, D.E. Stange, M. van den Born, J.H. van Es, M. van de Wetering et al., Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337 (6095), 730-735 (2012)
56. A.L. Welm, S. Kim, B.E. Welm, J.M. Bishop, MET and MYC cooperate in mammary tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 102(12), 4324-4329 (2005)
57. B. Mayer, J.P. Johnson, F. Leitl, K.W. Jauch, M.M. Heiss, F.W. Schildberg et al., E-cadherin expression in primary and metastatic gastric cancer: Down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 53(7), 1690-1695 (1993)
58. S. Sell, Cellular origin of cancer: Dedifferentiation or stem cell maturation arrest? Environ. Health Perspect. 101(Suppl 5), 15-26 (1993)
59. R. Fossmark, C.M. Zhao, T.C. Martinsen, S. Kawase, D. Chen, H.L. Waldum, Dedifferentiation of enterochromaffin-like cells in gastric cancer of hypergastrinemic cotton rats. APMIS. 113(6), 436-449 (2005)
60. A.V. Ougolkov, M.E. Fernandez-Zapico, V.N. Bilim, T.C. Smyrk, S.T. Chari, D.D. Billadeau, Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: Association with kinase activity and tumor dedifferentiation. Clin. Cancer Res. 12(17), 5074-5081 (2006)
61. Y. Oku, T. Shimoji, K. Takifuji, T. Hotta, S. Yokoyama, K. Matsuda et al., Identification of the molecular mechanisms for dedifferentiation at the invasion front of colorectal cancer by a gene expression analysis. Clin. Cancer Res. 14(22), 7215-7222 (2008)
62. R.J. Gilbertson, T.A. Graham, Cancer: Resolving the stem-cell debate. Nature 488(7412), 462-463 (2012)
63. J. Chen, Y. Li, T.S. Yu, R.M. McKay, D.K. Burns, S.G. Kernie et al., A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412), 522-526 (2012)
64. G. Driessens, B. Beck, A. Caauwe, B.D. Simons, C. Blanpain, Defining the mode of tumour growth by clonal analysis. Nature 488(7412), 527-530 (2012)
65. A.V. Salnikov, G. Kusumawidjaja, V. Rausch, H. Bruns, W. Gross, A. Khamidjanov et al., Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 275(2), 185-193 (2009)
66. T. Chiba, S. Miyagi, A. Saraya, R. Aoki, A. Seki, Y. Morita et al., The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 68(19), 7742-7749 (2008)
67. J.P. Li, J.Y. Zheng, J.J. Du, R. Zhang, A.G. Yang, What is the relationship among microRNA-181, epithelial cell-adhesion molecule (EpCAM) and beta-catenin in hepatic cancer stem cells. Hepatology 50(6), 2047-2048 (2009). author reply 448
68. S. Cairo, Y. Wang, A. de Reynies, K. Duroure, J. Dahan, M.J. Redon et al., Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc. Natl. Acad. Sci. U.S.A. 107(47), 20471-20476 (2010)
69. R.J. Isfort, D.B. Cody, C.J. Doersen, W.G. Richards, B.K. Yoder, J.E.Wilkinson et al., The tetratricopeptide repeat containing Tg737 gene is a liver neoplasia tumor suppressor gene. Oncogene 15(15), 1797-1803 (1997)
70. N. You, W. Liu, X. Zhong, R. Ji, M. Zhang, H. You et al., Tg737 inhibition results in malignant transformation in fetal liver stem/ progenitor cells by promoting cell-cycle progression and differentiation arrest. Mol. Carcinog. 51(8), 659-673 (2012)
71. B. Zhang, X. Pan, G.P. Cobb, T.A. Anderson, microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302(1), 1-12 (2007)
72. C.E. Rogler, MicroRNAs make inroads into liver development. Gastroenterology 136(3), 770-772 (2009)
73. E.J. Lee, Y. Gusev, J. Jiang, G.J. Nuovo, M.R. Lerner, W.L. Frankel et al., Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120(5), 1046-1054 (2007)
74. Q.W. Wong, R.W. Lung, P.T. Law, P.B. Lai, K.Y. Chan, K.F. To et al., MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135(1), 257-269 (2008)
75. R. Liu, Z. Zhou, D. Zhao, C. Chen, The Induction of KLF5 Transcription Factor by Progesterone Contributes to Progesterone-Induced Breast Cancer Cell Proliferation and Dedifferentiation. Mol. Endocrinol. 25(7), 1137-1144 (2011)
76. S. Chumsri, P. Phatak,M.J. Edelman, N. Khakpour, A.W. Hamburger, A.M. Burger, Cancer stem cells and individualized therapy. Cancer Genomics Proteomics 4(3), 165-174 (2007)
77. G. Federici, V. Espina, L. Liotta, K.H. Edmiston, Breast cancer stem cells: A new target for therapy. Oncology (Williston Park) 25 (1), 25-28 (2011)
78. D. Dingli, F. Michor, Successful therapy must eradicate cancer stem cells. Stem Cells 24(12), 2603-2610 (2006)
79. Y. Liu, W.L. Lu, J. Guo, J. Du, T. Li, J.W. Wu et al., A potential target associated with both cancer and cancer stem cells: A combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J. Control. Release 129(1), 18-25 (2008)
80. J. Gil, A. Stembalska, K.A. Pesz, M.M. Sasiadek, Cancer stem cells: The theory and perspectives in cancer therapy. J. Appl. Genet. 49(2), 193-199 (2008)
81. L. Milas, W.N. Hittelman, Cancer stem cells and tumor response to therapy: Current problems and future prospects. Semin. Radiat. Oncol. 19(2), 96-105 (2009)
82. Y.L. Hu, Y.H. Fu, Y. Tabata, J.Q. Gao, Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy. J. Control. Release 147(2), 154-162 (2010)
83. P. Aimola, V. Desiderio, A. Graziano, P.P. Claudio, Stem cells in cancer therapy: From their role in pathogenesis to their use as therapeutic agents. Drug News Perspect. 23(3), 175-183 (2010)
84. R. Uchibori, K. Ozawa, [Mesenchymal stem cells (MSCs) as a platform for cancer gene therapy]. Rinsho Ketsueki 51(11), 1641-1646 (2010)
85. L.J. Dai, M.R. Moniri, Z.R. Zeng, J.X. Zhou, J. Rayat, G.L. Warnock, Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett. 305(1), 8-20 (2011)
86. K. Shah, Mesenchymal stem cells engineered for cancer therapy. Adv. Drug Deliv. Rev. 64(8), 739-748 (2012)
87. I.S. Florian, C. Tomuleasa, O. Soritau, T. Timis, H. Ioani, A. Irimie et al., Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy. J. BUON 16(1), 16-23 (2011)
88. H. Beug, Breast cancer stem cells: Eradication by differentiation therapy? Cell 138(4), 623-625 (2009)
89. L. Wijaya, D. Agustina, A.O. Lizandi, M.M. Kartawinata, F. Sandra, Reversing breast cancer stem cell into breast somatic stem cell. Curr. Pharm. Biotechnol. 12(2), 189-195 (2011)
90. F.A. Kruyt, J.J. Schuringa, Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy. Biochem. Pharmacol. 80(4), 423-430 (2010)
91. S. Sell, Potential gene therapy strategies for cancer stem cells. Curr. Gene Ther. 6(5), 579-591 (2006)
92. S. Soltanian, M.M. Matin, Cancer stem cells and cancer therapy. Tumour Biol. 32(3), 425-440 (2011)
93. O.K. Okamoto, J.F. Perez, Targeting cancer stem cells with monoclonal antibodies: A new perspective in cancer therapy and diagnosis. Expert Rev. Mol. Diagn. 8(4), 387-393 (2008)
94. M.R. Alison, S.M. Lim, L.J. Nicholson, Cancer stem cells: Problems for therapy? J. Pathol. 223(2), 147-161 (2011)
95. E. Gorelik, A. Lokshin, V. Levina, Lung cancer stem cells as a target for therapy. Anticancer Agents Med Chem. 10(2), 164-171 (2010)
96. G.J. Leiros, M.E. Balana, Metastatic cancer stem cells: New molecular targets for cancer therapy. Curr. Pharm. Biotechnol. 12(11), 1909-1922 (2011)
97. M.E. Sehl, J.S. Sinsheimer, H. Zhou, K.L. Lange, Differential destruction of stem cells: Implications for targeted cancer stem cell therapy. Cancer Res. 69(24), 9481-9489 (2009)